# NCT06922591 (NCT06922591)

> Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06922591
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Tango Therapeutics, Inc.
- Conditions: PDAC; PDAC - Pancreatic Ductal Adenocarcinoma; NSCLC; RAS Mutation; MTAP Deletion; Lung Cancer; Pancreatic Cancer Metastatic; Thoracic Cancer
- Interventions: TNG462; RMC-9805; RMC-6236; mFOLFIRINOX; gemcitabine/nab-paclitaxel
- Enrollment: 183
- Primary outcome: Phase 1: Maximum Tolerated Dose
- Primary outcome: Phase 1: Maximum Tolerated Dose
- Primary outcome: Phase 2: Combination Anti-neoplastic Activity

## Indexed commentary on NCT06922591 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct06922591